The vaccine case detonated the earthquake, and 300 pharmaceutical companies should be careful!

Medical Network July 30th The vaccine case detonated another wave of earthquakes! The China Securities Regulatory Commission decided that it is necessary to force a delisting in the public health field.

On the evening of July 27, the China Securities Regulatory Commission issued <关于改革完善并严格实施上市公司退市制度的若干意见>Decisions (hereinafter referred to as "Decisions"). Listed companies with major violations in areas such as public health and safety must be forced to withdraw from the market!

Some commentators believe that the incentives for the SFC to make a quick decision may be related to the vaccine case.

The most important one of the revision of the CSRC's delisting system is to clarify that if a listed company involves major illegal activities in the areas of public safety, ecological security, production safety and public health and safety, the stock exchange shall make a suspension in strict accordance with the law. Termination of the company's stock trading decision.

This "Decision" came into effect on July 27, 2018. The longevity creature touched the delisting red line.

The CSRC stated that before the implementation of the "Decision", if the listed company has been identified as a major illegal act or has been transferred to the public security organ according to law and has been decided to terminate the listing, the original provisions are applicable. In addition to the above, the listed company is determined by this decision. The suspension of listing of major illegal acts before the implementation of the law, termination of listing, the application of this decision.

In fact, on the evening of July 24, Changsheng Biology announced that the company's stock has been implemented with other risk warnings since its opening on July 26, 2018. The company's stock abbreviation has been changed from 'Longevity' to 'ST Changsheng'. The stock name plus ST is mainly to give investors a warning, the stock has investment risks)

Changsheng Biotechnology recognizes that if the company is finally found to have committed a major illegal act or transferred to the public security organ due to the investigation of the investigation, according to the relevant provisions of the Shenzhen Stock Exchange Listing Rules, the company's stock may be subject to the risk of delisting, suspended. Risk of listing or termination of listing.

Changchun Changsheng's vaccine case, although it has not yet settled, it is not difficult to predict, then the drug regulatory department will definitely drug Production, circulation, the strictest rectification of war.

After the outbreak of the Shandong vaccine in March 2016, the circulation of rectification and high pressure, the investigation of violations, violations continued throughout the 2016. Hundreds of officials fell, the frequency of drug inspections increased, a large number of drugs were reorganized, medicine People pressure mountain big.

The turmoil in the Changchun Changsheng Vaccine case was even bigger and became a social event. The high-level anger, the public denounced, the image of the pharmaceutical industry was shamed. There is reason to believe that the industry rectification will be more intense and deeper. .